Pulmonary Patient Articles & Analysis
13 news found
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac ...
” “I am also pleased to report that eNOfit™, our novel miniaturized mobile-wearable nitric oxide device designed to provide ’on-the-go’ treatment for patients suffering from severe COPD and ILD (pulmonary fibrosis), is scheduled to enter clinical trials in the next few months. ...
Glenn Crater, CMO at Inversago pointed out: “These encouraging results obtained using a well-accepted preclinical model for lung fibrosis show that zevaquenabant hold promise as a novel treatment option for pulmonary fibrosis. With only two treatments for IPF available, the potential of zevaquenabant in this indication as an add-on therapy is important for ...
"The Adient fully absorbable filter solution creates a new paradigm to protect patients from pulmonary embolus," Dr. Durack shared. "I am thrilled to be part of the collaborative team of Adient, Cordis, and Cordis-X and to see this groundbreaking approach come to fruition." ...
He is also a member of the Board of Directors of the Medical Device Manufacturers Association and Chairman of the Board of Gala Therapeutics, a privately held medical device company that is dedicated to developing disease-modifying therapies for patients with pulmonary diseases. Previously, Mr. Godshall was President, Chief Executive Officer and Director of ...
Improvements in the field of mechanical circulatory support and the further development of ventricular assist devices enable critically ill heart patients to recover and bridge the often very long waiting periods for a donor heart. Berlin Heart has developed a cannula that intends to a more convenient surgical handling during implantation and an adaptation to the individual needs ...
Aidoc, the leading provider of enterprise AI solutions, announced today the launch of an industry first: an AI-based automated activation solution that facilitates rapid risk assessment and care coordination for high-risk pulmonary embolism (PE) patients. Aidoc’s PE Care Coordination includes Aidoc’s FDA-cleared solution for triage and notification ...
ByAidoc
The partnership is intended to provide thoracic radiologists and pulmonary embolism management programs timely notification of pulmonary embolism cases combined with automated RV/LV ratio calculations to potentially improve patient severity assessment and expedite treatment. ...
ByAidoc
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
Current methods of respiratory muscle training cannot be used when patients are sedated or delirious, which is common among critically ill patients. ...
Liberate Medical, a medical device company developing novel non-invasive electrical muscle stimulation devices to help patients with pulmonary conditions, today announced that it has received CE marking for its VentFree™ Respiratory Muscle Stimulator and ISO 13485 certification for its quality management system. ...
“The results from this successful pilot study support our belief that VentFree has the potential to save lives, reduce morbidity and significantly decrease hospital costs for these patients.” About Prolonged Mechanical Ventilation Approximately 40% of patients who need mechanical ventilation need it for more than four days, and the number of these ...
” About Prolonged Mechanical Ventilation Approximately 40% of mechanically ventilated patients require more than four days of ventilator support, and the number of these patients is increasing at 5.5% per year. ...